CELLIVERY THERAPEUTICS, INC.CC

CELLIVERY THERAPEUTICS, INC.

6,680KRWD
−2,850−29.91%
At close at 2023 Mar 26, 22:44 UTC
KRW
No trades
See on Supercharts

268600 fundamentals

Key facts

Market capitalization‪244.25 B‬KRW
Basic EPS (TTM)−543.12KRW
Founded2014
CEODae-Woong Cho
About

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmaceutical products. Its products include improved cell-permeable parkin (iCP-Parkin), cell/tissue permeable frataxin (CP-FXN), improved cell-permeable SOCS3 (iCP-SOCS3), cell-permeable BMP2 (CP-BMP2), cell-permeable truncated SOCS3 (CP-SD), improved cell-permeable nuclear import inhibitor (iCP-NI), and others. The company was founded by Dae-Woong Cho on March 14, 2014 and is headquartered in Seoul, South Korea.

Ownership
‪‪37.18 M‬‬
Free Float shares
‪‪31.96 M‬‬ (85.94%)
Closely held shares
‪‪5.23 M‬‬ (14.06%)
Free Float shares
‪‪31.96 M‬‬ (85.94%)
Closely held shares
‪‪5.23 M‬‬ (14.06%)
Capital structure
Market cap
‪‪244.25 B‬‬
Debt
‪‪35.36 B‬‬
Minority interest
‪‪−2.17 B‬‬
Preferred stock
‪‪15.57 M‬‬
Cash & equivalents
‪‪133.78 M‬‬
Enterprise value
‪‪277.32 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪244.25 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
14.43x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
14.43x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24

Growth and Profitability

Company’s recent performance and margins

Performance
‪−4,865.00%‬
‪−3,665.00%‬
‪−2,465.00%‬
‪−1,265.00%‬
‪−65.00%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−18.00 B‬‬
‪‪−9.00 B‬‬
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−2.00 B‬‬
‪‪−1.00 B‬‬
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−2.00 B‬‬
‪‪−1.00 B‬‬
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Research and Development Service
By country
Period: 2023
South Korea
Overseas

Dividends

Dividend yield, history and sustainability

268600 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−16.00 B‬‬
‪0.00‬
‪‪16.00 B‬‬
‪‪32.00 B‬‬
‪‪48.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪11.00 B‬‬
‪‪22.00 B‬‬
‪‪33.00 B‬‬
‪‪44.00 B‬‬
Assets
Liabilities